Abstract: The invention relates to novel combined compositions for combatting plant, animal and sanitarian as well as forestry, horticultural and warehouse pests. These compositions contain a pyrethroid-type insecticide as an insecticidally active ingredient and at least one fungicide inhibiting the ergosterol biosynthesis as activity-strengthening agent as well as optionally piperonylbutoxide and other additives.The advantages of the compositions according to the invention consist therein that the activity-strengthening substances used are fungicidal agents widely used and have an advantageous toxicology. The activity-strengthening agent exerts a synergistic effect together with the pyrethroid-type insecticide.The combinations according to the invention bear an outstanding importance in the protection of stored crops.

Abstract: The present invention relates to novel 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide derivatives of the general formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R stands for a C.sub.1-12 alkyl group optionally substituted by a C.sub.1-4 alkoxycarbonyl group; a C.sub.3-9 cycloalkyl, adamantyl or optionally substituted phenyl group;R.sup.1 means hydrogen or a C.sub.1-4 alkyl group; orR and R.sup.1 together form a --(CH.sub.2).sub.n -- chain, wherein n is 4, 5 or 6;R.sup.2 stands for hydrogen, a C.sub.1-4 alkyl group or halogen;R.sup.3 represents hydrogen or a C.sub.1-4 alkyl group; andm is 0 or 1.The compounds of the general formula (I) possess a gastroprotective effect and are useful for the prevention and therapy of ulcers of the stomach and the small intestine.

Abstract: An anhydrous transdermal composition is disclosed comprising in a 20 to 100% lyotropic liquid crystalline arrangement:5 to 15 weight % of optically active or racemic N-methyl-N-(1-phenyl-2-propyl)-2-propynylamine or N-methyl-N-{1-(4-fluorophenyl)-2-propyl}-2-propynylamine or a pharmaceutically acceptable salt thereof;40 to 70% by weight of liquid polyethylene glycol;10 to 20% by weight of solid polyethylene glycol;2 to 30% by weight of a nonionic surface active agent;2 to 20% by weight of propylene glycol, and if desired,0.5 to 2% by weight of a polymer, the a value of which is greater than 0.6, andoptionally, in an amount needed up to 100% an emulsifying agent.

Abstract: The invention relates to a new process for the preparation of antibacterial compounds of the Formula I ##STR1## wherein R.sup.1 stands for phenyl substituted by 1 or 2 halogen atoms;R.sup.2 stands for piperazinyl or 4-methyl-piperazinyl;and pharmaceutically acceptable salts thereof which comprises using a compound of the Formula II ##STR2## wherein R stands for halogen or an aliphatic acyloxy group containing 2 to 6 carbon atoms or an aromatic acyloxy group containing 7 to 11 carbon atoms andR.sup.4 stands for fluorine or chlorine as a starting material.

Abstract: A process is disclosed for the preparation of a compound of the Formula (VI) ##STR1## wherein X is a hydrogen atom, or OH,Y is a hydrogen atom, OH or a methyl group,R.sup.2 is a CH--COOR group, or a group of the formula (XI) ##STR2## and R is a C.sub.1 to C.sub.2 alkyl group, which comprises the step of: reacting a condensed salt of the Formula (IV) ##STR3## wherein Me is Na.sup.+ or K.sup.+, with a reactive derivative of trifluoromethane-sulfonic acid of the Formula (V)F.sub.3 C--SO.sub.2 OH.The compounds of the Formula (VI) are intermediates in the preparation of penicillins and cephalosporins with antibiotic activity.

Abstract: The invention relates to a new process for the preparation of compounds of the general Formula I ##STR1## wherein R stands for piperazinyl, 4-methyl-piperazinyl or 4-ethyl-piperazinyl group and pharmaceutically acceptable salts thereof which comprises reacting a compound of the general Formula II ##STR2## wherein R.sup.1 and R.sup.2 stand for halogen, for an aliphatic acyloxy group containing 2 to 6 carbon atoms and optionally substituted by halogen, or for an aromatic acyloxy group containing 7 to 11 carbon atoms with a piperazine derivative of the general Formula III ##STR3## wherein R.sup.3 stands for hydrogen, methyl or ethyl or a salt thereof and subjecting the compound of the general Formula IV ##STR4## thus obtained wherein R, R.sup.1 and R.sup.2 are as stated above to hydrolysis after or without isolation and if desired converting the compound of the general Formula I thus obtained into a salt thereof or setting free the same from its salt.

Abstract: The invention relates to inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof and pharmaceutical compositions containing the same.The inclusion complex of 3-morpholino-sydnonimine or its salt formed with cyclodextrin derivative is prepared bya) reacting the 3-morpholino-sydnonimine or its salt in an aqueous medium with a cyclodextrin derivative and the complex is isolated from the solution by dehydratation, orb) high energy milling of 3-morpholino-sydnonimine or its salt and a cyclodextrin derivative.

Abstract: The invention relates to a new process for the preparation of compounds of the Formula I ##STR1## (wherein R stands for hydrogen or methyl) and pharmaceutically acceptable salts thereof which comprises reacting a compound of the Formula V ##STR2## (wherein R.sup.1 and R.sup.2 stand for an aliphatic acyloxy group comprising 2-6 carbon atoms and optionally substituted by halogen: or for an aromatic acyloxy group comprising 7-11 carbon atoms) with an amine of the Formula VI ##STR3## (wherein R has the same meaning as stated above) or a salt thereof and subjecting the compound of the Formula VII ##STR4## thus obtained (wherein R, R.sup.1 and R.sup.2 are as stated above) to hydrolysis after or without isolation and if desired converting the compound of the Formula I thus obtained into a salt thereof or setting free the same from its salt.The compounds of the Formula I are known antibacterial agents.

Abstract: A method of using a compound of the Formula (V) ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, wherein R.sup.1 and R.sup.2 are each C.sub.1 to C.sub.6 aliphatic acyloxy, unsubstituted or substituted by halogen, or are each C.sub.7 to C.sub.

Abstract: A pure crystalline O-(2-hydroxy-3-piperidino-1-propyl) nicotinic acid amidoxime base of the Formula (Ib) ##STR1## is disclosed characterized by a melting point of 70.degree. to 73.degree. C., giving, when dissolved in an amount of 1 to 10 ml of concentrated sulfuric acid, a yellow homogeneous solution, and showing the following spectral characteristics:IR spectrum (kBr): .gamma. --O--C.dbd.N 1642 cm.sup.-1.sup.1 H-NMR spectrum (CDCL.sub.3, .delta. ppm): 1.48 m, (6H), CH.sub.2 -piperidine; 2.42 m, (6H), 3.times.CH.sub.2 --N; 3.36, br, (1H), CH--O; 4.08 m, (3H), 1--CH.sub.2, OH; 5.2, br, (2H), NH.sub.2 ; 7.30 m (1H), pyridine-5'; 7.92 m, 4', 8.62 m (1H), 6', 8.88 m, (1H), 2'.

Abstract: The invention relates to a plant protecting or veterinary or additive composition, containing beside the active ingredient and other usually applied auxiliaries, such as solid and liquid carrier(s), surface active agent(s) and further additive(s), one or more surface active agent(s) of the general formulae (I) ##STR1## or a mixture thereof, wherein R, R.sup.2, R.sup.3 and R.sup.4 are independently from each other hydrogen atom, an organic or inorganic cation or a group of the general formula --(CH.sub.2 --CH.sub.2 --O).sub.n R.sup.1, whereinR.sup.1 is a C.sub.10-20 alkyl group andn is an integer from 4 to 20, with the provisio that from among the substituents R, R.sup.2 and R.sup.3 at least one is a group of the general formula (CH.sub.2 --CH.sub.2 O).sub.n R.sup.1.

Abstract: The invention relates to antibacterial pseudo-primycin complexes of formula (I) ##STR1## to the components and acid addition salts thereof, as well as to the preparation of these compounds and to the pharmaceutical compositions containing said compounds as active ingredient.In the formula (I) R.sup.1 is butyl, pentyl or hexyl, R.sup.2 is hydrogen, hydroxyl or O-arabinose and X is organic or inorganic acid ion.

Abstract: The present invention relates to novel 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide derivatives of the general formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R stands for a C.sub.1-12 alkyl group optionally substituted by a C.sub.1-4 alkoxycarbonyl group; a C.sub.3-9 cycloalkyl, adamantyl or optionally substituted phenyl group;R.sup.1 means hydrogen or a C.sub.1-4 alkyl group; orR and R.sup.1 together form a --(CH.sub.2).sub.n -- chain, wherein n is 4, 5 or 6;R.sup.2 stands for hydrogen, a C.sub.1-4 alkyl group or halogen;R.sup.3 represents hydrogen or a C.sub.1-4 alkyl group; andm is 0 or 1.The compounds of the general formula (I) possess a gastroprotective effect and are useful for the prevention and therapy of ulcers of the stomach and the small intestine.

Abstract: The invention relates to a process for the preparation of pure isoflavone derivatives of the general formula (I), ##STR1## wherein R stands for hydrogen or isopropyl,R.sup.2 and R.sup.3 stand for hydrogen or C.sub.1-2 alkoxy by reacting a rezorcinol-derivative of the general formula (III) ##STR2## wherein R.sup.2 and R.sup.3 are as given above with ethyl-orthoformiate of the formula (IV)(C.sub.2 H.sub.5 O).sub.3l CH (IV)in the presence of a base and optionally by alkylating the product.

Abstract: The invention relates to novel stable aqueous primycin solutions containing 0.5 to 1.75% by mass/volume of primycin sulfate or 2.5 to 9% by mass/volume of a complex of primycin N-methylpyrrolidone and 2 to 15% by mass/volume of pyroglutamic acid, preferably L-pyroglutamic acid or a soluble salt, preferably the sodium salt thereof as calculated for the volume of the solution to be prepared and 40 to 60% by volume of isopropanol as calculated for the volume of the solution to be prepared as well as water in an amount adding up to 100%. The stable, aqueous primycin solutions are topical antibiotics.

Abstract: The inventions is a purer form of O-(2-hydroxy-3-piperidino-1-propyl)nicotinic acid amidoxime hydrochloride.

Abstract: The invention relates to an improved, large scale process for the preparation of compounds of formula (I) ##STR1## wherein R is halogen atom or hydroxyl,R.sup.2 is hydrogen atom or hydroxyl,R.sup.3 and R.sup.4 are hydrogen or alkoxy having 1-6 carbon atoms.

Abstract: The present invention relates to a pharmaceutical composition comprising as active ingredient a compound of the Formula I ##STR1## wherein R.sup.1 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; phenyl alkyl having 7 to 10 carbon atoms; phenyl; or cycloalkyl comprising 3 to 8 carbon atoms;R.sup.2 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; alkyl comprising 1 to 8 carbon atoms substituted by halogen, hydroxy, alkoxy having 1 to 4 carbon atoms or by one or two phenyl groups; phenyl; or cycloalkyl having 3 to 8 carbon atoms,with the proviso that groups R.sup.1 and R.sup.2 together contain at least three carbon atoms. The invention also relates to a process for the preparation of compounds of the Formula I by methods known per se.

Abstract: The invention relates to a stabile, aqueous suspoemulsion containing as active ingredient 0.2-5 weight % of primycin, 5-25 weight % of propylene glycol, 0.5-5 weight % of non-ionic surface active agent, if desired 15 weight % of auxiliary agent and distilled water in an amount necessary to 100 weight %, as well as to a process for the preparation thereof.

Abstract: The invention relates to novel compounds of the general formula (I), ##STR1## The compounds of the invention antagonize the effects of constrictive mediators, e.g. histamine, acetylcholine or serotonin; they show an antiallergic action and possess an antiinflammatory effect. Thus, these compounds can therapeutically be used as bronchodilators as well as antiallergic or antiinflammatory drugs, particularly in the treatment of bronchial asthma.